Aquis Stock Exchange Weekly Highlights 28/10/24

Igraine Plc announced the grant of exclusive investment rights over GEM Energia Limited, a renewable energy company specialised in the development of battery energy storage systems across the UK through its wholly-owned subsidiaries. The Company also announced the establishment of a Convertible Loan Facility with Vela Technologies plc with a minimum £200,000 commitment. Read more

Ananda Developments Plc announced that two of its patent-pending cannabinoid medicines, MRX2 and MRX2T, will be used in two National Institute for Health and Care Research and NHS co-funded Phase IIIa epilepsy clinical trials, involving up to 500 patients in total. The trials will be run by investigators at University College London and Great Ormond Street Hospital.

Melissa Sturgess, CEO, commented: "We are proud that our MRX2 and MRX2T products meet the rigorous requirements for these trials and have received the support of internationally respected clinician investigators with expertise in refractory epilepsies. Our clear objective is to deliver licensed CBD-based medicines which will be available on the NHS." Read more

EDX Medical Group Plc announced that the Company has received a strategic investment of £300,000 through the placing of new ordinary shares in the Company at a price of 11p per share, a 22% premium to the market price. The investment will be used to support the expansion of EDX Medical's capabilities and operations.

Professor Sir Chris Evans, OBE, Founder, commented: “We are delighted that another high net worth, experienced healthcare investor with a track record in successful medical ventures has chosen to support EDX Medical. This investor's extensive network of healthcare contacts in the Gulf is also of considerable importance to the marketing of our new products in that region.” Read more

Oscillate plc announced the commencement of operational activity at its flagship licences in northern Minnesota, USA. The Company highlighted that they have begun their interpretation of existing gravity and magnetic data and acquired key equipment, including a Hydrogen soil-gas sensor, in preparation for the initiation of the field programme.

Steve Xerri, CEO, commented: “With the acquisition of a hydrogen soil-gas sensor we have now passed a significant milestone in starting operations for what we believe will be an exciting field season. The first phase of work will provide essential data necessary to progress to the in-field operations, where we will scout for potential hydrogen sources throughout our expansive acreage. I look forward to updating shareholders as we move towards an exciting period of activity in line with our near term goals of further evaluating the hydrogen potential of our acreage.” Read more

🗓️ Event: The 3rd Aquis Showcase Event will be held at the Royal College of Surgeons, London on the 12th November 2024. Listen to 16 AQSE listed companies each delivering rapid fire pitches, all under 8-minutes. Secure your ticket now with 20% off using the code ‘AQ20’ here.🌟